Clozapine Pharmacogenetic Studies in Schizophrenia: Efficacy and Agranulocytosis

• Main Authors: Shusuke Numata, Hidehiro Umehara, Tetsuro Ohmori, Ryota Hashimoto
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2018-09-01
• Series: Frontiers in Pharmacology
• Subjects: clozapine; schizophrenia; clinical response; agranulocytosis; pharmacogenetics; SNP
• Online Access: https://www.frontiersin.org/article/10.3389/fphar.2018.01049/full

Clozapine is an efficacious atypical antipsychotic for treatment-refractory schizophrenia. Clinical response and appearance of adverse events vary among individual patients receiving clozapine, with genetic and non-genetic factors potentially contributing to individual variabilities. Pharmacogenetic studies investigate associations between genetic variants and drug efficacy and toxicity. To date, most pharmacogenetic studies of clozapine have been conducted through candidate gene approaches. A recent advance in technology made it possible to perform comprehensive genetic mapping underlying clinical phenotypes and outcomes, which allow novel findings beyond biological hypotheses based on current knowledge. In this paper, we will summarize the studies on clozapine pharmacogenetics that have extensively examined clinical response and agranulocytosis. While there is still limited evidence on clozapine efficacy, recent genome-wide studies provide further evidence of the involvement of the human leukocyte antigen (HLA) region in clozapine-induced agranulocytosis.